• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    CMC Pharmaceuticals

    Syngene International Ltd.

    Quotient Sciences

    Federal Equipment Company
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    CMC Pharmaceuticals

    Syngene International Ltd.

    Quotient Sciences

    Federal Equipment Company
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    ExcellGene, Bharat Biotech & University of Sydney to Develop Variant-Proof SARS-CoV-2 Vaccine

    ExcellGene to produce complex chimeric Spike antigens using its engineered CHOExpress-cell based technology.

    ExcellGene, Bharat Biotech & University of Sydney to Develop Variant-Proof SARS-CoV-2 Vaccine
    07.26.22
    ExcellGene SA, privately held and founded 2001, has announced its role in the recently approved consortium funding through the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership of public, private, philanthropic and civil society organizations founded to develop vaccines against future epidemics.
     
    The consortium partnership strives to advance a new vaccine concept that confers highly cross-reactive protection against numerous SARS-CoV-2 variants of concern (VoCs) as well as other Betacoronaviruses. ExcellGene will produce complex chimeric Spike antigens using its engineered CHOExpress-cell based technology. The Swiss company will use insights from several scientific and technical disciplines along with artificial intelligence to identify the most promising antigenic structure.
     
    ExcellGene is a leader in the development and manufacturing of complex proteins (DNA to product) for therapeutic or prophylactic applications, an example being trimeric spike proteins of SARS-CoV-2. Together with Bharat Biotech, and Prof. Jamie Triccas and his team at the University of Sydney, Australia, ExcellGene will generate and screen a large and diverse library of chimeric spike proteins to identify highly cross-reactive antigen structures that recall past and possibly future variants. CEPI will provide up to US $19.3 million in funding to develop a ‘variant-proof’ SARS-CoV-2 vaccine candidate for phase I clinical trials.
     
    With this new funding, ExcellGene expands on a collaboration with the team of Prof. Jamie Triccas that started in early 2020. ExcellGene began to produce Wuhan trimeric SARS-CoV-2 spike proteins in March 2020, and subsequently Alpha, Beta, Delta and, recently, Omicron variants. The Company delivered these antigens to its partners as highly purified, stabilized, trimeric spike proteins that had been engineered for high-yield production.
     
    By April/May 2021, the Sydney group had verified that such trimeric adjuvanted spike preparations were highly immunogenic in preclinical models. Blocking virus infection was shown in-vitro and in preclinical models with virus variants different from the immunizing antigen.
     
    Earlier, ExcellGene had conducted research in an EU-Horizon 2020 funded project on an Ebola candidate antigen molecule that resulted in sterilizing immunity in pre-clinical challenge models.

    Finding and Testing the Ideal Antigen

    An entirely new “chimeric” spike antigen complex, different from any protein of existing SARS-CoV-2 variants, will be generated. It is expected that such a trimeric spike protein, composed of combined mutations that characterize virus variants of concern from 2020-2022 (VoCs), will induce a wider range of cross-reactivity against historic or future variants than any of the individual virus variants did before.
     
    To do so, the ExcellGene team will produce complex chimeric proteins using its engineered CHOExpress-cell based technology, and Prof. Triccas and his team will assess the range of immune responses in various animal species and undertake a Phase 1 trial to assess safety and immunogenicity of the lead candidate.
     
    Theoretically, a near infinite number of such chimeric molecules can be designed. ExcellGene will reduce the diversity of such structures through artificial intelligence mediation analysis in combination with structure-function insights gained in examining the evolution of spike versions that resulted in the emergence of VoCs. Variable immune responses in vaccinated people with different strains will also be taken into consideration. Thus, a more manageable number of putative antigens can be tested in ExcellGene’s high-throughput transient gene and stable pool CHO-based expression system for development and manufacturability.

    A Modern Approach to Developing Vaccines

    Maria Wurm, Dr. es. sci., CEO of ExcellGene, thinks the company’s technology shows the value of using a CHO-based technology platform to produce optimized antigens for vaccine production.
     
    “This new CEPI partnership is a great opportunity to showcase what is possible in the manufacturing of highly complex antigen structures, consisting of computer-designed individual monomers, for a potential variant-proof Covid-19 vaccine. We are excited to work closely with our consortium partners to reach this goal, and we hope it will contribute towards the science for this and other novel protein-based vaccines. Ultimately, we wish to contribute to solving major health care challenges, as most strikingly exposed by COVID-19, using technology and scale-up approaches that successfully provided tons of protein therapeutics made in cultivated animal cells in bioreactors.”
     
    Prof Jamie Triccas, Sydney Institute for Infectious Diseases, The University of Sydney said: “We are delighted to partner with ExcellGene, Bharat Biotech and the CEPI organization to progress our platform for the development of broadly protective COVID-19 vaccines. Our mission is to deliver safe, affordable and highly effective vaccines to combat existing and future SARS-CoV-2 variants, and our international consortium is well placed to achieve this goal.”
     
    Dr. Krishna Ella, chairman and managing director, BBIL said: “The global threat of SARS-CoV-2 is continuing with new infections over and over again, irrespective of prior infections or vaccinations. Thus, more applied research has to be done, both in laboratories like those of Prof. Triccas, and in a company like ExcellGene, that can provide entirely new antigen concepts that combine insights into SARS-CoV-2 gained over the last two and a half years. Being a successful vaccine producer, particularly in the COVID-19 field, does not allow us to rest. We are therefore very pleased in having convinced the CEPI organization that our partnership over three continents is a robust solution that promises to open a new door for a future cross-reactive vaccine.”
    Related Searches
    • Biologics, Proteins, Vaccines
      Loading, Please Wait..
      Breaking News
      • Univercells Expands into the U.S. With New Offices in Andover, MA
      • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
      • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
      • Sanner Group Opens Second Manufacturing Facility in China
      • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
      View Breaking News >
      CURRENT ISSUE

      September 2023

      • Pharma Supply Chains: From Fragile to Agile
      • Overcoming Stressors in Knowledge Transfer
      • Innovations in Pharma Packaging
      • HPAPI Manufacturing Trends
      • Sustainable Packaging in Pharma: No Longer a Pipe Dream
      • Revolutionizing Pharma’s Supply Chain
      • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
      • Solving Pharma’s Underlying Rebate Leakage Problem
      • Advanced Manufacturing and a Roadmap to the Facility of the Future
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
      Natrol Launches First Non-Melatonin Sleep Supplement
      Metagenics Releases Consumer Survey on Menopausal Support Supplement
      Coatings World

      Latest Breaking News From Coatings World

      California Sports Surfaces Celebrates 70 Years
      ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
      AkzoNobel Shares Sustainable Architectural Solutions at Conference
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
      SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
      ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Univercells Expands into the U.S. With New Offices in Andover, MA
      Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
      Ionis, Roche Partner on RNA-targeted Programs for AD and HD
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
      74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
      Stoelzle Glass Group Names New CEO
      Happi

      Latest Breaking News From Happi

      The Estée Lauder Companies Launches 2023 Breast Cancer Campaign
      BASF Personal Care Introduces New Cosmetic Ingredient
      Breakfast with Oral Care Benefits?
      Ink World

      Latest Breaking News From Ink World

      Siegwerk’s Climate Targets Validated by SBTi
      ROSS Offering Cost-Effective, Expertly Reconditioned Equipment
      Amcor plc Adds Lucrèce Foufopoulos-De Ridder to Board of Directors
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      SABIC and partners launch bio-based IML solution for food packaging
      tesa completes expansion of Michigan manufacturing facility
      Comexi and Asahi to host 'Effortless Platemaking' event
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Greentech Introduces Air Filter with Advanced Odor Elimination
      Ontex Divests Pakistan Operations to ASAIA Holding
      Goodnites Bedwetting Underwear Recognized by Good Housekeeping
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
      ChitogenX Granted New U.S., Canadian ORTHO-R Patent
      Centinel Spine prodisc System Surpasses 2,500-Implant Milestone
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
      Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More
      SCHOTT Strengthens Glass Substrate Portfolio

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login